CTXR Quote, Financials, Valuation and Earnings

Inari Medical has a net margin of -- compared to Citius Pharmaceuticals's net margin of -11.97%. Citius Pharmaceuticals's return on equity of -- beat Inari Medical's return on equity of -17.68%.

Citius Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 995.51%. On the other hand Inari Medical has an analysts' consensus of $74.12 which suggests that it could fall by -6.53%. Given that Citius Pharmaceuticals has higher upside potential than Inari Medical, analysts believe Citius Pharmaceuticals is more attractive than Inari Medical.

Citius Pharmaceuticals has a beta of 1.302, which suggesting that the stock is 30.18% more volatile than S&P 500. In comparison Inari Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inari Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Inari Medical pays out -- of its earnings as a dividend.

Citius Pharmaceuticals quarterly revenues are --, which are smaller than Inari Medical quarterly revenues of $153.4M. Citius Pharmaceuticals's net income of -$10.8M is higher than Inari Medical's net income of -$18.4M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Inari Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus 8.01x for Inari Medical. Usually stocks with elevated PS ratios are considered overvalued.

Nuvalent has a net margin of -- compared to Citius Pharmaceuticals's net margin of --. Citius Pharmaceuticals's return on equity of -- beat Nuvalent's return on equity of --.

Citius Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 995.51%. On the other hand Nuvalent has an analysts' consensus of $115.08 which suggests that it could grow by 58.97%. Given that Citius Pharmaceuticals has higher upside potential than Nuvalent, analysts believe Citius Pharmaceuticals is more attractive than Nuvalent.

Citius Pharmaceuticals has a beta of 1.302, which suggesting that the stock is 30.18% more volatile than S&P 500. In comparison Nuvalent has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuvalent offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Nuvalent pays out -- of its earnings as a dividend.

Citius Pharmaceuticals quarterly revenues are --, which are smaller than Nuvalent quarterly revenues of --. Citius Pharmaceuticals's net income of -$10.8M is higher than Nuvalent's net income of -$84.3M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Nuvalent's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus -- for Nuvalent. Usually stocks with elevated PS ratios are considered overvalued.

Predictive Oncology has a net margin of -- compared to Citius Pharmaceuticals's net margin of -895.23%. Citius Pharmaceuticals's return on equity of -- beat Predictive Oncology's return on equity of -232.54%.

Citius Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 995.51%. On the other hand Predictive Oncology has an analysts' consensus of -- which suggests that it could grow by 150%. Given that Citius Pharmaceuticals has higher upside potential than Predictive Oncology, analysts believe Citius Pharmaceuticals is more attractive than Predictive Oncology.

Citius Pharmaceuticals has a beta of 1.302, which suggesting that the stock is 30.18% more volatile than S&P 500. In comparison Predictive Oncology has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.224%.

Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Predictive Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Predictive Oncology pays out -- of its earnings as a dividend.

Citius Pharmaceuticals quarterly revenues are --, which are smaller than Predictive Oncology quarterly revenues of $345.7K. Citius Pharmaceuticals's net income of -$10.8M is lower than Predictive Oncology's net income of -$3.1M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Predictive Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus 3.80x for Predictive Oncology. Usually stocks with elevated PS ratios are considered overvalued.

Revance Therapeutics has a net margin of -- compared to Citius Pharmaceuticals's net margin of -63.65%. Citius Pharmaceuticals's return on equity of -- beat Revance Therapeutics's return on equity of --.

Citius Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 995.51%. On the other hand Revance Therapeutics has an analysts' consensus of $7.64 which suggests that it could grow by 132.13%. Given that Citius Pharmaceuticals has higher upside potential than Revance Therapeutics, analysts believe Citius Pharmaceuticals is more attractive than Revance Therapeutics.

Citius Pharmaceuticals has a beta of 1.302, which suggesting that the stock is 30.18% more volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.857, suggesting its less volatile than the S&P 500 by 14.274%.

Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend.

Citius Pharmaceuticals quarterly revenues are --, which are smaller than Revance Therapeutics quarterly revenues of $59.9M. Citius Pharmaceuticals's net income of -$10.8M is higher than Revance Therapeutics's net income of -$38.1M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus 1.24x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.